Skip to content

Study · Not a test of the peptide alone · 1968

4 results

Glucagon test for insulinoma: a chemical study in 25 cases.

Marks V, Samols E

Journal of clinical pathology1 May 1968Cited by 31 (Europe PMC)

PMID4301688 (opens in a new tab)PMCIDPMC473794 (opens in a new tab)DOI10.1136/jcp.21.3.346 (opens in a new tab)PepBankPUB-04301688
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Glucagon.

  1. 01HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In insulinoma patients, intravenous glucagon produced an abnormally large plasma insulin rise in 10 of 14 patients compared with normal controls.

    In plain wordsCompared with normal controls, 10 of 14 insulinoma patients had an abnormally large insulin rise after intravenous glucagon.

    Peptide
    Glucagon
    Outcome
    IncreasePlasma insulin response
    Study

    n = 14

    Comparator
    Normal controls
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Patients with abnormally large insulin rise
    10 patients
    14 insulinoma patients

    Source sentences

    Summary
    In 14 insulinoma patients the response of venous blood glucose and also plasma insulin to lmg of intravenous glucagon was compared with 10 normal controls; there was an abnormally large rise of plasma insulin in 10 of the 14 patients, and in the majority the venous blood glucose was below normal throughout the test.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  2. 02HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In most insulinoma patients, venous glucose remained below normal throughout the intravenous glucagon test.

    In plain wordsIn most insulinoma patients, blood glucose remained below normal throughout the intravenous glucagon test.

    Peptide
    Glucagon
    Outcome
    DecreaseVenous glucose during test
    Study

    n = 14

    Comparator
    Normal controls
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In 14 insulinoma patients the response of venous blood glucose and also plasma insulin to lmg of intravenous glucagon was compared with 10 normal controls; there was an abnormally large rise of plasma insulin in 10 of the 14 patients, and in the majority the venous blood glucose was below normal throughout the test.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  3. 03HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In insulinoma patients, intramuscular glucagon produced a normal initial capillary glucose rise compared with normal controls.

    In plain wordsIn insulinoma patients, glucagon produced a normal initial glucose rise compared with normal controls.

    Peptide
    Glucagon
    Outcome
    Not applicableInitial capillary glucose rise
    Study

    n = 13

    Comparator
    Normal controls
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The capillary blood glucose response to lmg of intramuscular glucagon was determined in 13 patients with insulinoma and in 33 normal controls; the insulinoma patients showed a normal initial rise, but this was followed by an abnormally large fall, reaching hypoglycaemic levels between 90 and 180 minutes in every case.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

  4. 04HumanNot a test of Glucagon aloneNon-randomized trialActivity measurement

    In insulinoma patients, intramuscular glucagon produced an abnormally large glucose fall, reaching hypoglycaemia between 90 and 180 minutes in every case.

    In plain wordsIn insulinoma patients, glucagon caused an abnormally large glucose fall, reaching hypoglycaemia between 90 and 180 minutes.

    Peptide
    Glucagon
    Outcome
    DecreaseDelayed hypoglycaemia
    Study

    n = 13

    Comparator
    Normal controls
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Time to hypoglycaemia
    90 to 180 minutes
    intramuscular glucagon

    Source sentences

    Summary
    The capillary blood glucose response to lmg of intramuscular glucagon was determined in 13 patients with insulinoma and in 33 normal controls; the insulinoma patients showed a normal initial rise, but this was followed by an abnormally large fall, reaching hypoglycaemic levels between 90 and 180 minutes in every case.

    In this study, Glucagon was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Glucagon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.